Introduction
Many plants have been identified as good sources of natural antioxidants, which protect against 7 139
The blood samples were centrifuged at 3000 rpm at 4 o C, for 15 min and the serum was stored 140 at -80 o C until further analysis. Finally, dissected prostate glands were weighed and stored at -141 80 o C liquid nitrogen for further analysis. Body weight of rats was measured at the beginning 142 and the end of the experimental period.
143
Assessment of serum testosterone and DHT levels 144 Serum testosterone and DHT were determined using commercial enzyme-linked 145 immunosorbent assay (ELISA) kit (ALPCO Diagnostics, NH, USA) according to the 146 manufacturer's protocol.
147
Histological study 148 Paraffin embedded prostate tissues were cut into 5µm sections. After deparaffinization and 149 dehydration, sections were subjected to hematoxylin and eosin (H&E) staining and examined 150 using light microscope (Nikson ECLIPSE Ni-U, Tokyo, Japan) at × 400 magnification. Images 151 were taken from 10 randomly selected fields, and epithelial thickness was measured using 152 Image J software (Image J v46a; NIH, USA).
153
Western blot analysis of prostatic hyperplasia-related protein 154 Collected cells and frozen prostate tissue samples were lysed with RIPA buffer, centrifuged 155 12,000 rpm for 20 min at 4 o C and the supernatant was used for the western blotting. Extracted 156 proteins were separated on 8-10 % SDS-polyacrylamide gels and transferred onto PVDF 9 183 Phytochemical compounds in the SC extract such as hederacoside D ( Fig 1A) and morroniside 184 ( Fig 1C) were identified and quantified by using HPLC. Hederacoside D showed the 185 characteristic peak at 39.52 min ( Fig 1B) , while morroniside at 6.53 min ( Fig 1D) and the 186 concentrations were found as 25 mg/g and 1.5 mg/g respectively.
187
Cell viability and in vitro western blotting 188 To study the cytotoxicity of SC extract on LNCaP cells, the MTT assay was performed. As 189 shown in Fig. 2A , there was no significant difference in cell viability between SC treated cells 190 and control cells. However, the exposure to 100 µg/mL of SC markedly decreased the cell 191 viability up to 86.73%, demonstrating that high concentration of SC inhibits cell viability by 192 its toxicity. Highest cell viability was shown by the cells treated with 50 µg/mL SC.
193
In this study, we investigated the effect of SC treatment on androgen receptor (AR), prostate 194 specific antigen (PSA), and 5α-reductase type 2 in LNCaP cells using western blot ( Fig. 2B ).
195
As shown in Fig finasteride showed significantly (p < 0.01) decreased PW relative to the BPH group. Similarly, 208 SC50 and SC200 groups also exhibited significantly (p < 0.001, p < 0.01 respectively) 209 decreased PW compared with the BPH group. However, no significant differences in BW were 210 observed among the groups (Fig. 3B ). Moreover, relative prostatic weight was significantly (p 211 < 0.001) elevated in the BPH group compared to the control, while Fina group exhibited 212 significantly (p < 0.001) decreased values in comparison to the BPH group (Fig. 3C ). The 213 groups SC50 and SC200 also showed these values that were significantly (p < 0.001, p < 214 0.01respectively) decreased than those of the rats in the BPH group. These results proved that 215 SC is a potential treatment for modulating the prostate size of the TP-induced BPH model.
216

SC mediated downregulation of serum testosterone and DHT in
217
BPH rats 218 In this experiment, we studied serum testosterone and DHT as they have a fundamental role in 219 progression of BPH. As shown in Fig. 4A , a significant (p < 0.01) increase in serum 220 testosterone level was shown in the BPH group compared with the control group. In contrast, 221 rats in the groups of Fina, SC50 and SC200 showed significantly (p < 0.01) decreased 222 testosterone levels relative to the BPH group. Similarly, the groups Saw, SC25 and SC100 also 223 showed significant (p < 0.05) increase in the testosterone level. Like the serum testosterone, 224 serum DHT level also significantly (p < 0.01) increased in the BPH group (Fig. 4B ). By 225 contrast, the rats in all the SC treated groups showed significantly (p < 0.001) reduced DHT 226 level. Like rats in the SC treated groups, those in the finasteride treated group also showed To demonstrate the TP-induced histological alterations, H&E staining was carried out (Fig. 231 5A). There were no histological changes associated with the control group. However, BPH 232 group showed disrupted morphology such as significant thickening, hypertrophy and 233 hyperplasia with papillary projections in the epithelium. Further, the lumen diameter was also 234 widened as compared to the control group. Mild epithelial hyperplasia was shown by both Fina 235 and Saw groups relative to the BPH group. SC treatment has been shown to markedly reduce 236 the above morphological abnormalities in the BPH rats, in a dose dependent manner. As shown 237 in Fig, 5B , rats in the BPH group exhibited significantly (p < 0.001) increased prostatic 238 epithelial thickness compared with those of the control group. In contrast, all the BPH rats, 239 which have been treated, showed significant (p < 0.001) reduction in prostatic epithelial 240 thickness compared to the control group. Aforementioned results suggest that SC treatment has 241 an ability to attenuate the abnormal histological changes, thereby reduce the prostate weight in 242 the BPH rats.
243
In vivo western blotting 244 For in vitro analysis, western blotting was performed to evaluate AR and PSA protein 245 expression in the prostate tissue ( Fig. 6A ). As shown in Fig. 6 B, C, AR exhibited a significant 246 (p < 0.01) increase and PSA showed markedly increased expression in the BPH group 247 compared with the control group. The rats treated with finasteride and SC, showed significantly 248 (p < 0.05) reduced expression of AR and markedly decreased PSA expression relative to the 249 BPH group. These results indicated that SC treatment has an ability to suppress the androgen 250 signaling in prostate cells of BPH rats.
251
Immunohistochemical study of rat prostatic tissue 12 252 In this study, we investigated the immunoexpression of 5α-reductase type 2 and PCNA. As 253 shown in Fig. 7A , IHC of prostate tissue indicated that the rats in the control group had no 254 abnormalities; however, those in the BPH and Saw groups showed increased expression of 255 type-2 5α-reductase. Notably, finasteride and SC treatment reversed the effect of TP, and SC 256 treatment reduced the type-2 5α-reductase expression, in a dose-dependent manner. We also 257 studied the anti-proliferative effect of SC by measuring the expression of PCNA in the prostate 258 tissues and PCNA-positive cells were characterized by brown-stained nuclei, in both glandular 259 epithelium and stroma. As shown in Fig. 7B , rats in the control group had no expression of 
289
Testosterone is an androgen produced by Leydig cells of the testis, while DHT is an important 290 byproduct of testosterone and the most potent androgen in men, which is involved in 291 development and aging. Further, type 2 5α-reductase is considered to be as the convertor of 292 testosterone to its metabolite DHT [27] [28] [29] [30] [31] . Our study demonstrated significantly increased 293 testosterone and DHT levels in the serum of BPH group as compared to the control. On the 294 other hand, a significant reduction was observed in aforementioned androgens in the finasteride 295 and SC treated rats as compared to the BPH group. These data evidenced that SC treatment has 296 an ability to regulate androgens and their byproducts, and thereby attenuate BPH development.
297
Androgens affect gene expression in various kinds of tissues and cells by binding with the AR, 298 which has been linked to prostate cancer [32, 33] . DHT has a higher affinity for AR as 299 compared to testosterone; and in the prostate, the interaction between DHT and AR results in 14 300 the production of proteins such as PSA. PSA is a glycoprotein in humans, encoded by the 301 KLK3 gene, a member of the kallikrein-related peptidase family, and secreted by the prostatic 302 epithelial cells. It plays a role in various functions during copulation and fertilization [34] . As 303 serum PSA levels are frequently raised in prostate disorders such as BPH and prostate cancer, 304 it is used as a clinical maker for disease prognosis [35] . In this study, in vitro and in vivo 305 western blotting revealed that the increased AR, PSA and 5α-reductase type 2 in BPH condition 306 can be significantly inhibited with finasteride and SC treatments. These findings proved that 307 SC extract is a potential option to suppress androgen signaling in prostatic cells.
308
In the current study, we also performed the IHC to examine the expression of 5α-reductase type 309 2 and PCNA. PCNA is a marker of cell proliferation, particularly expressed in proliferating 310 cell nuclei, and plays a crucial role in certain physiological and pathological conditions.
311
Disruption of balance between cell death and cell proliferation can cause abnormal growth of 312 prostate gland, leading to BPH [36, 37] . Oxidative stress is also mediated by the mechanisms 313 that are associated with prostate proliferation [38] . In this study, significantly increased PCNA 314 expression was detected in the BPH group rats as compared to the control rats. In contrast, both 315 finasteride and SC treated rats exhibited significant reduction in PCNA count relative to the 316 BPH group. Moreover, IHC of type 2 5α-reductase showed elevated expression in BPH group, 317 while both finasteride and SC intervention reversed that effect. Together, these findings proved 318 that SC extract can be a possible treatment for BPH via anti-proliferative activity. In conclusion, the findings of our study revealed that SC treatment significantly reduced the 322 prostate hyperplasia and prostate size. In addition, SC extract had an ability to inhibit type 2 323 5α-reductase expression, thereby preventing the conversion of testosterone into its byproduct 15 324 DHT, suggesting that SC is a potential treatment for regulating androgen signaling in prostatic 325 cells. Moreover, intervention of SC resulted in anti-proliferative activity, thereby prevent the 326 development and progression of BPH. Therefore, this investigation evidenced that assortment 327 of Stauntonia hexaphylla and Cornus officinalis can protect against testosterone-induced 328 benign prostatic hyperplasia through its anti-inflammatory and anti-proliferative activity. Use 329 of SC extract as a therapeutic intervention for the treatment of BPH warrants further 330 investigation.
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Data availability 333 The data used to support the finding of this experiment are available from the corresponding 334 author upon request.
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